AmeReGen CEO Dr Ernest G Hope MD PhD interview on PwC Start Up Radio on Stem Cell Breakthrough CITA.

Dec. 4, 2008 - PRLog -- Georgetown, Cayman Islands

Stealthy and privately held AmeReGen BioPharmaceuticals INC, SPC., announced that the rare and much requested PwC radio show interview with its CEO Dr. Hope, MD, PhD (Stanford University, USA) is now readily available for download on the web. In the course of the interview with Dr Hope as one of the recognized “fathers of stem cells” – he introduced the concept of re-embryonalyzation of adult cells as early as two decades ago – details are revealed how AmeReGen and its porfolio AmeReGen-ImmunoCure INC became the de-facto global leaders of routinely approved CITA adult (ethical) stem cell therapeutics for cancer with their virtually side-effect-free advanced cancer treatments that can be quasi-robotically produced and delivered virtually anywhere in the world.  

This interview and certain general information on AmeReGen BioPharmaceuticals INC and on AmeReGen-ImmunoCure Corp. are now available at www.stemcellsatwork.com

In the course of the interview details of the proprietary manufacturing process of AmeReGen ImmunoCure Corp and of the routinely achieved medical results with these individualized high tech therapeutics were revealed, that are in routine use in cancer patients for half a decade in Europe.

Privately held AmeReGen-ImmunoCure is a pharmaceutical grade (stem) cell manufacturing think tank and OEM manufacturer to AmeReGen BioPharmaceuticals INC and has proprietary technology and global exclusive manufacturing rights for the highest quality assured mass-production of CITA T-cell therapeutics for many of the hardest to treat cancers.

CITA therapy has become routinely available in the EU, but not yet approved by the FDA for use in the United States. With no ethical dilemmas, "adult T-stem cell" therapy utilizes a person's own blood T-cells, and boosts the cancer immune surveillance system to prevent, reject, or destroy advanced cancer with little if any side effects; even in cancer's clinically most advanced and problematic multi-drug resistant forms, called MDR+ cancer.

The exclusive and proprietary (stem) cell manufacturing technologies leveraged by AmeReGen-ImmunoCure Corp. includes patented breakthrough inventions developed at Stanford University in Palo Alto, California, as well as in stem cell hot bed BioBay/Silicon Valley, California and other leading sites.

AmeReGen ImmunoCure Corp has recently been noted for a purchase transaction that acquired 15% of its equity for an estimated value of nearly $300 million, by a publicly traded and diversified portfolio holding, Petroleum Communication Holdings, Inc. (PTLC.PK) which thus diversified into therapeutic cancer (stem) cell therapeutics as a high-growth industry and “to diversify PTLC's holdings that represent major growth potential,” as was learned from their recent press release in this regards.

DISCLAIMER:

This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These include, but are not limited to, statements regarding the Company's plans, intentions and expectations.

Forward-looking statements are based on the subjective opinions and estimates of management at the time the statements are made. Such statements are inherently subject to a variety of risks, uncertainties and other factors that could cause actual results to differ materially from those expected or implied by the forward-looking statements possibly expressed or implied. These factors include general economic and business conditions nationally, internationally and in the regions and countries in which AmeReGen operates; market, regulatory, medical scientific, or demographic changes; technology changes; competition; changes in business strategy or development plans; the ability to access capital markets; the ability to attract and retain qualified personnel; existing or future governmental regulations. Given these factors, investor and analysts should not rely on any of the possibly contained forward-looking statements of this press release or make investment decisions of any kind solely or partially based on the information provided. This PR is of informational nature, only. AmeReGen ImmunoCure Corp. is not seeking investments, nor is it offering securities of any kind to the public.


Contact:
    AmeReGen BioPharmaceuticals INC (SPC)
    Investor Relations
    +1-415-730-2500
    AMEREGEN@STEMCELLSATWORK.COM

# # #

Privately held AmeReGen-ImmunoCure is a pharmaceutical grade (stem) cell manufacturing think tank and OEM manufacturer to AmeReGen BioPharmaceuticals INC and has proprietary technology and global exclusive manufacturing rights for the highest quality assured mass-production of CITA T-cell therapeutics for many of the hardest to treat cancers.